Triamcinolone Acetonide Intravitreal Injection Shortage
Last Updated: March 29, 2024
Status: Current
Products Affected - Description
-
- Triesence intravitreal suspension for injection, Harrow Eye, LLC, 40 mg/mL, 1 mL vial, NDC 00065-0543-01
Reason for the Shortage
-
- Novartis divested Triesence to Harrow Eye, LLC in late-November 2023.
- Harrow Eye, LLC has Triesence on shortage due to manufacturing delays related to good manufacturing practices.
- They are the sole suppliers.
Available Products
-
- There are no presentations available
Estimated Resupply Dates
-
- Harrow Eye, LLC has Triesence 40 mg/mL 1 mL vials on long-term back order and the company cannot estimate a release date.
Updated
Updated March 29, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 30, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.